Risk factors for pneumonitis in patients with non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy plus chemotherapy has become a standard of care for patients with advanced non‐small cell lung cancer (NSCLC). Pre‐existing interstitial lung disease (ILD) is a risk factor for drug‐induced pneumonitis caused by chemotherapy or ICI monotherapy. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Teppei, Shimizu, Junichi, Oya, Yuko, Watanabe, Naohiro, Hasegawa, Takaaki, Horio, Yoshitsugu, Inaba, Yoshitaka, Fujiwara, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888158/
https://www.ncbi.nlm.nih.gov/pubmed/35044093
http://dx.doi.org/10.1111/1759-7714.14308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888158/
https://www.ncbi.nlm.nih.gov/pubmed/35044093
http://dx.doi.org/10.1111/1759-7714.14308

Ejemplares similares